{"version": "20220721", "payload": [{"gene": "3CLpro", "position": 15, "mutations": "3CLpro:G15S", "comment": "G15S is a common polymorphism (prevalence 0.5%) which was present in the Lambda variant. It has been reported to reduce the biochemical activity of nirmatrelvir by 4-fold[^FDA21d].", "date_added": "2022-02-01", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 50, "mutations": "3CLpro:L50F", "comment": "L50F has been selected during in vitro passage experiments with nirmatrelvir in combination with E166V[^Zhou22c] and another Mpro inhibitor in combination with E166A+L167F[^Jochmans22]. Alone it is not associated with reduced nirmatrelvir susceptibility. It is also associated with greatly reduced Mpro function. However, it appears to contribute to reduced nirmatrelvir susceptibility when it occurs with the mutations listed above. It has a global prevalence <0.00001%.", "date_added": "2022-06-08", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 135, "mutations": "3CLpro:T135I", "comment": "T135I is a rare variant (prevalence 0.02%) which has been reported to reduce the biochemical activity of nirmatrelvir by 4-fold[^FDA21d].", "date_added": "2022-02-01", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 144, "mutations": "3CLpro:S144AFGMY", "comment": "S144A is an extremely rare Mpro mutation (prevalence < 0.0001%) in the enzyme substrate cleft which has been selected during in vitro passage in a mouse hepatitis virus (MHV) model that has been reported to reduce the biochemical inhibition of nirmatrelvir by 233-fold[^FDA21d]. S144FGMY are rare mutations (prevalence <0.0001%) that reduce the nirmatrelvir inhibitory activity between 19-30 fold, while reducing Mpro enzymatic activity by <10-fold (range 2.6-8.0-fold)[^Hu22b].", "date_added": "2022-02-01", "date_updated": "2022-07-01", "": ""}, {"gene": "3CLpro", "position": 164, "mutations": "3CLpro:H164N", "comment": "H164N is an extremely rare Mpro mutation (prevalence 0.0004%) in the enzyme substrate cleft that has been reported to reduce the biochemical inhibition of nirmatrelvir by 6-fold[^FDA21d].", "date_added": "2022-02-01", "date_updated": "2022-07-01", "": ""}, {"gene": "3CLpro", "position": 165, "mutations": "3CLpro:M165T", "comment": "M165T reduces the biochemical inhibition of nirmatrelvir by 30-fold while reducing Mpro enzymatic activity by 8-fold[^Hu22b]. Its prevalence is about 0.00001%.", "date_added": "2022-07-01", "date_updated": "", "": ""}, {"gene": "3CLpro", "position": 166, "mutations": "3CLpro:E166AVQ", "comment": "E166V has been selected in vitro during passage in the presence of nirmatrelvir in combination with L50F[Zhou22c]. E166A has been selected in vitro during passage in the presence of another Mpro inhibitor in combination with L50F+L167F[^Jochmans22]. E166V in combination with L50V reduced nirmatelvir susceptibity by 80-fold without significantly reducing SARS-CoV-2 replication[^Zhou22c]. In cell culture, E166V reduced nirmatrelvir susceptibility 265-fold[^Iketani22b]. E166A in combination with L50V+L167F reduced nirmatrelvir susceptibility >20-fold but the combination was associated a replication capacity of only 15%[^Jochmans22]. L50F, E166A/V, and L167F have global prevalences <0.00001%. E166Q reduces nirmatrelvir inhibitory activity by 12-fold without reducing enzymatic activity. It has a prevalence of about 0.1%", "date_added": "2022-06-08", "date_updated": "2022-07-05", "": ""}, {"gene": "3CLpro", "position": 177, "mutations": "3CLpro:H172YQ", "comment": "H172Y is an extremely rare Mpro mutation (prevalence 0.0005%) in the enzyme substrate cleft that has been reported to reduce the inhibitory activity of nirmatrelvir by 65-fold[^FDA21d]. H172Q is an extremly rare mutation (prevalence 0.00002%) that reduces the inhibitory activity of nirmatrelvir by >42-fold while reducing enzymatic activity by 3-fold[^Hu22b]", "date_added": "2022-02-01", "date_updated": "2022-07-01", "": ""}, {"gene": "3CLpro", "position": 189, "mutations": "3CLpro:Q189K", "comment": "Q189 is in a flexible loop that closes over the Mpro substrates and potentially interacts with Mpro inhibitors including nirmatrelvir[^Flynn22]. Q189K is an extremely rare Mpro mutation (prevalence 0.004%) in the enzyme substrate cleft that has been reported to reduce the biochemical activity of nirmatrelvir by 92-fold[^FDA21d].", "date_added": "2022-02-01", "date_updated": "2022-06-05", "": ""}, {"gene": "3CLpro", "position": 248, "mutations": "3CLpro:D248E", "comment": "D248E is a rare variant (prevalence 0.01%) which has been reported to reduce the biochemical activity of nirmatrelvir by 4-fold[^FDA21d].", "date_added": "2022-02-01", "date_updated": "", "": ""}, {"gene": "nsp6", "position": 106, "mutations": "nsp6:106del, nsp6:107del, nsp6:108del", "comment": "The Alpha, Beta, Gamma, Eta, Iota, Lambda, and Omicron variants each contain the same deletion of amino acids 106 to 108 in the non-structural protein 6 (nsp6) a component of the SARS-CoV-2 membrane-tethered replication complex that is also involved in antagonizes host-responsiveness to interferons[^Annavajhala21][^Martin21][^Skidmore21][^Xia20c][^Plante21].", "date_added": "2021-04-05", "date_updated": "2021-11-27", "": ""}, {"gene": "RdRP", "position": 166, "mutations": "RdRP:V166L", "comment": "V166L has been selected during in vitro passage with remdesivir[^Checkmahomed22]. It is associated with approximately 2-fold reduced remdesivir susceptibility. V166L has been reported in approximately 0.003% of published SARS-CoV-2 isolates.", "date_added": "2022-06-18", "date_updated": "", "": ""}, {"gene": "RdRP", "position": 323, "mutations": "RdRP:P323L", "comment": "P323L (Orf1b:P314L) emerged in the same virus containing D614G. It has now reached a global prevalence of 95%, which is slightly lower than that of D614G (98%). Its impact on RdRp function has not been well studied.", "date_added": "2021-07-21", "date_updated": "2022-07-21", "": ""}, {"gene": "RdRP", "position": 480, "mutations": "RdRP:F480L", "comment": "F480L is a homolog of a mutation that emerged during in vitro passage in a related coronavirus. It has been shown to reduce the susceptibility of SARS-CoV-1 by 6-fold when it occurred in combination with V557L[^Agostini18]. It has a global prevalence of 0.0006%.", "date_added": "2022-02-08", "date_updated": "2022-07-21", "": ""}, {"gene": "RdRP", "position": 484, "mutations": "RdRP:D484Y", "comment": "D484Y has been reported to emerge in one patient receiving remdesivir[^Martinot21]. It has a global prevalence of 0.001%.", "date_added": "2022-02-08", "date_updated": "2022-07-21", "": ""}, {"gene": "RdRP", "position": 557, "mutations": "RdRP:V557L", "comment": "V557L is a homolog of a mutation that emerged during in vitro passage in a related coronavirus. It has been shown to reduce the susceptibility of SARS-CoV-1 by 6-fold when it occurred in combination with F480L[^Agostini18]. It has a global prevalence of 0.0005%.", "date_added": "2022-02-08", "date_updated": "2022-07-21", "": ""}, {"gene": "RdRP", "position": 759, "mutations": "RdRP:S759A", "comment": "S759A has been selected in vitro during the passage of SARS-CoV-2 in the presence of GS-441524, the parent compound of remdesivir. S759 occurs in the RdRP SDD active site motif and is therefore analogous to the cytosine analog mutations that occur in the YMDD motif of HIV and HBV. In combination with V792I, another GS-441524-selected mutation, it is associated with 7.3 fold reduced GS-441524 susceptibility[^Stevens22]. It has a prevalence <0.00001%.", "date_added": "2022-05-16", "date_updated": "2022-07-21", "": ""}, {"gene": "RdRP", "position": 792, "mutations": "RdRP:V792I", "comment": "V792I has been selected in vitro during the passage of SARS-CoV-2 in the presence of GS-441524, the parent compound of remdesivir. It is associated with 2.6 fold reduced GS-441524 susceptibility[^Stevens22]. It has also been selected in two immunocompromised patients receiving remdesivir[^Hogan22].", "date_added": "2022-05-16", "date_updated": "2022-07-08", "": ""}, {"gene": "RdRP", "position": 802, "mutations": "RDRP:E802AD", "comment": "E802D has been selected in vitro when SARS-CoV-2 is cultured in the presence of increasing concentrations of remdesivir[^Szemiel21]. It has also been reported to emerge in a patient with persistent infection despite remdesivir treatment[^Gandhi21]. E802A and E802D reduce susceptibility to remdesivir by 2 and 2.5 to 6-fold, respectively[^Szemiel21][^Gandhi22]. E802D and E802A have global prevalences of 0.003% and 0.0003%, respectively.", "date_added": "2021-11-18", "date_updated": "2022-05-16", "": ""}, {"gene": "S", "position": 5, "mutations": "S:L5F", "comment": "L5F is a common NTD mutation, which alone has not been associated with reduced susceptiiblity to any mAbs or CP.", "date_added": "2021-11-23", "date_updated": "", "": ""}, {"gene": "S", "position": 13, "mutations": "S:S13I", "comment": "S13I results in reduced binding to multiple NTD-targeting mAbs[^McCallum21b].", "date_added": "2021-04-08", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 18, "mutations": "S:L18F", "comment": "L18F is an NTD mutation present in the Beta and Gamma variants. It is associated with reduced susceptibility to several NTD-binding mAbs but by itself does not appear to reduce CP or VP susceptibility[^Wang21b][^McCallum21].", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 20, "mutations": "S:T20N", "comment": "T20N is an NTD mutation present in the Gamma variant. It is associated with reduced susceptibility to several NTD-binding mAbs[^Wang21d]", "date_added": "2021-11-23", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 69, "mutations": "S:69del, S:70del", "comment": "NTD deletions at positions 69 and 70 have been reported in multiple variants including the Omicron BA.1, BA.4, and BA.5 variants. They are associated with increased virus replication[^Kemp21][^Meng21]. They do not appear to reduce susceptibility to neutralizing mAbs or convalescent plasma[^McCallum21][^Shen21][^Wang21b][^Rees-Spear21]. This deletion prevents the amplification of one of three genomic segments in a commonly used diagnostic PCR assay, resulting in a phenomenon referred to as S-gene target failure (SGTF). ", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 80, "mutations": "S:D80A", "comment": "D80A is an NTD mutation present in the Beta variant. It is associated with reduced susceptibility to some NTD-targeting mAbs but not to plasma from convalescent or vaccinated persons[^Wang21b].", "date_added": "2021-04-08", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 141, "mutations": "S:141del, S:142del, S:143del, S:144del, S:145del, S:146del ", "comment": "NTD deletions between positions 141-146 occur in the Alpha and Omicron BA.1 and BA.2 variants. They are associated with resistance to several NTD-binding neutralizing mAbs but do not appear to reduce the neutralizing activity of plasma from convalescent or vaccinated persons[^Li20h][^McCallum21][^Wang21b].", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 152, "mutations": "S:W152C", "comment": "W152C is an NTD mutation first present in the Epsilon variant. It results in reduced binding to multiple NTD-targeting mAbs[^McCallum21b].", "date_added": "2021-04-08", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 215, "mutations": "S:D215G", "comment": "D215G is a mutation present in Beta variant. It appears to have little or no effect on Ab neutralizing susceptibility[^Wang21b].", "date_added": "2021-04-10", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 222, "mutations": "S:A222V", "comment": "A222V is a common NTD mutation. It is generally not considered an Ab-escape mutation, although ts effect on NTD-targeting mAbs and plasma from convalescent and vaccinated persons has not been well studied.", "date_added": "2021-04-07", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 242, "mutations": "S:242del, S:243del, S:244del", "comment": "NTD deletions between positions 242-244 are present in the Beta variant. They are associated with resistance to several NTD-binding neutralizing mAbs. They have rarely been associated with reduced neutralization activity of plasma from convalescent persons but remain fully susceptible to plasma from vaccinated persons[^McCallum21][^Wang21b][^Wang21f].", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 246, "mutations": "S:R246I", "comment": "R246I is a rare mutation present in a small proportion of Beta variant isolates usually in combination with a deletion encompassing positions 242-244, which reduces susceptibility to multiple NTD-targeting mAbs[^Wang21b].", "date_added": "2021-04-10", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 247, "mutations": "S:247del, S:248del, S:249del, S:250del, S:252del, S:252del, S:253del", "comment": "This NTD deletion has been reported in the Lambda variant and is associated with greatly reduced susceptibility to several NTD-binding neutralizing Abs.", "date_added": "2021-07-15", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 253, "mutations": "S:D253GY", "comment": "D253G/Y are NTD mutations in a commonly recognized Ab epitope and are associated with reduced susceptibility to some NTD-targeting mAbs. D253G is in the Iota variant first identified in New York.", "date_added": "2021-04-05", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 337, "mutations": "S:P337HLRT", "comment": "P337H/L/R/T are extremely rare mutations. P337L/R are associated with >100-fold reduced sotrovimab susceptibility[^FDA21b][^Cathcart21]. P337H/T are associated with 5-7-fold reduced sotrovimab susceptibility[^FDA21b][^Cathcart21]. P337L is associated with 5-fold reduced susceptibility to imdevimab[^FDA20].", "date_added": "2021-08-04", "date_updated": "", "": ""}, {"gene": "S", "position": 339, "mutations": "S:G339D", "comment": "G339D is an RBD core mutatiom that is present in the Omicron VOCs. It has a slightly elevated escape fraction (0.048) for sotrovimab in the Bloom laboratory DMS assay but is susceptible to sotrovimab in most neutralization assays.", "date_added": "2021-11-26", "date_updated": "2022-06-04", "": ""}, {"gene": "S", "position": 340, "mutations": "S:E340AKG", "comment": "E340K developed in 5 subjects receiving sotrovimab in the COMET-ICE trial[^FDA21b] but otherwise mutations at this position are extremely rare. E340A/K are associated with >100-fold reduced sotrovimab susceptibility[^FDA21b][^Cathcart21]. E340G is associated with 27-fold reduced sotrovimab susceptibility[^FDA21b][^Cathcart21].", "date_added": "2021-08-04", "date_updated": "2022-01-14", "": ""}, {"gene": "S", "position": 346, "mutations": "S:R346K", "comment": "R346K is present in the Mu (B.1.621) variant and in about 10% of Omicron BA.1 variants (BA.1.1). Alone is associated with >100-fold reduced susceptibility to C135[^Weisblum20]. In the context of Omicron BA.1, it further reduces the susceptibility of cilgavimab by about 5-10-fold and of romlusevimab susceptibility by about 10-fold[^Liu21l]. ", "date_added": "2021-08-04", "date_updated": "2022-06-04", "": ""}, {"gene": "S", "position": 346, "mutations": "S:R346SI", "comment": "R346S is found in the C36.3 lineage in which it occurs in combination with L452R. It has been shown to reduce susceptibility to C135 and to several mAbs that are not in clinical trials[^Weisblum20][^Muecksch21][^Yi21]. R346I is associated with >200-fold reduced susceptibility to cilgavimab[^FDA21c].", "date_added": "2022-06-04", "date_updated": "", "": ""}, {"gene": "S", "position": 367, "mutations": "S:V367F", "comment": "V367F is present in the variant A23.1. It has been reported to increase ACE2 binding affinity[^Ou21] but it has not been reported to reduce susceptibility to mAbs or polyclonal Abs in convalescent or vaccinee plasma.", "date_added": "2021-08-06", "date_updated": "", "": ""}, {"gene": "S", "position": 371, "mutations": "S:S371L", "comment": "S371L is an RBD core mutation present in the Omicron BA.1 variant. It reduces susceptibility to etesevimab (6.2 to 31-fold), imdevimab (11 to 74-fold), and sotrovimab (7.4 to 240-fold).", "date_added": "2021-11-26", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 371, "mutations": "S:S371F", "comment": "S371F is an RBD core mutation present in the Omicron BA.2, BA.4, and BA.5 variants. It reduces susceptibility to etesevimab (143 to 630-fold), casirivimab (14 to 28-fold), imdevimab (11 to 126-fold), sotrovimab (5.5 to 21-fold), and tixagevimab (6.3 to 31-fold).", "date_added": "2022-06-05", "date_updated": "", "": ""}, {"gene": "S", "position": 384, "mutations": "S:P384L", "comment": "P384L is an uncommon RBD mutation that is not associated with reduced susceptibility to any mAbs or to convalescent plasma.", "date_added": "2021-09-03", "date_updated": "", "": ""}, {"gene": "S", "position": 405, "mutations": "S:D405N", "comment": "D405N is present in the Omicron BA.2, BA.4, and BA.5 variants. It reduces susceptibility to etesevimab (16 to 26-fold) and casirivimab (11 to 14-fold).", "date_added": "2022-06-05", "date_updated": "", "": ""}, {"gene": "S", "position": 408, "mutations": "S:R408S", "comment": "R408S is present in the Omicron BA.2, BA.4, and BA.5 variants. By itself, it does not appear to reduce susceptibility to any of the clinical stage mAbs.", "date_added": "2022-06-05", "date_updated": "", "": ""}, {"gene": "S", "position": 417, "mutations": "S:K417NT", "comment": "K417N/T are ACE2-binding site RBM mutations present in the Beta (K417N), Gamma (K417T), and Omicron (K417N) variants. K417N has also been reported in two sublineages of the Delta variant (AY.1 and AY.2). Both mutations reduce ACE2 binding[^Collier21][^Greaney20]. Both K417N and K417T confers >100-fold reduced susceptibility to etesivimab and ~30-fold reduced susceptibility to casirivimab but retain susceptibility to the remaining mAbs in advanced clinical development. K417N/T alone retain full susceptibility to plasma samples from convalescent persons.", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 439, "mutations": "S:N439K", "comment": "N439K is an ACE2-binding site RBD mutation reported to increase ACE2 affinity[^Chen20m][^Starr20][^Thomson21]. It causes high-level resistance to imdevimab[^Starr21][^Wang21e]. Viruses containing N439K usually retain full susceptibility to convalescent or vaccinee plasma[^Greaney21][^Shen21][^Thomson21].", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 440, "mutations": "S:N440K", "comment": "N440K is an increasingly common RBD mutation, which is found in each of the Omicron variants and in several previous global lineages. It causes high-level resistance to imdevimab and C135, two mAbs that bind the RBD core region[^Weisblum20][^Wang21]. It retains susceptibility to sotrovirmab, another core-binding mAb [^Cathcart21]. Based on limited data, it does not appear to reduce susceptibility to most convalescent plasma samples[^Wang21].", "date_added": "2021-04-13", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 444, "mutations": "S:K444QNER", "comment": "S:K444QN are extremely rare mutations associated with reduced susceptibility to imdevimab and C135, mAbs that bind the RBD core[^Baum20][^Weisblum20][^Starr21]. K444QER are associated with >200-fold reduced susceptibility to cilgavimab[^FDA21c].", "date_added": "2021-07-21", "date_updated": "2022-01-15", "": ""}, {"gene": "S", "position": 445, "mutations": "S:V445A", "comment": "S:V445A is a rare mutation associated with >100-fold reduced imdevimab susceptibility[^Baum20][^Copin20] and 3-fold reduced sotrovimab susceptibilty[^Cathcart21].", "date_added": "2021-08-04", "date_updated": "", "": ""}, {"gene": "S", "position": 446, "mutations": "S:G446V", "comment": "G446V was reported to occur in 4.5% of REGN-COV2 (casirivimab+imdevimab) study participants at an allele fraction above 15%[^Copin21]. It causes high-level resistance to imdevimab and C135[^Rothenberger21][^Weisblum20]. It retains susceptibility to casirivimab and against most of the other clinical stage mAbs. ", "date_added": "2021-04-10", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 446, "mutations": "S:G446S", "comment": "G446S is a present in Omicron BA.1. It is associated with high-level resistance to imdevimab and low-level resistance to cilgavimab. ", "date_added": "2022-06-04", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 449, "mutations": "S:Y449H", "comment": "Y449H is a rare mutation found in the A.29 and C.1.2 lineages. In A.29 it occurs in combination with N501Y and in C.1.2 it occurs in combination with E484K + N501Y. It reduces susceptibility to C548 an RBM class II Ab[^Muecksch21].", "date_added": "2021-08-31", "date_updated": "", "": ""}, {"gene": "S", "position": 450, "mutations": "S:N450DK", "comment": "N450D/K are rare mutations. N450D is associated with reduced susceptiblity to imdevimab[^Baum20]. N450K is associated with 9-fold reduced cilgavimab susceptibility[^FDA21c], and reduced susceptibility to several mAbs that are not in clinical trials[^Yi21].", "date_added": "2021-08-06", "date_updated": "2022-01-15", "": ""}, {"gene": "S", "position": 452, "mutations": "S:L452R", "comment": "L452R is present in the Delta, Epsilon, Kappa, Omicron BA.4, and Omicron BA.5 variants. It is associated with reduced susceptibility to several RBM class II mAbs including bamlanivimab but not to the other FDA EUA-approved mAbs[^Copin21][^Li20h][^Liu21][^FDA21][^Wang21e]. It has also been associated with low-level reductions in susceptibility to about one-third of convalescent and vaccinee plasma samples[^Greaney21c][^Ferreira21].", "date_added": "2021-04-05", "date_updated": "2022-06-04", "": ""}, {"gene": "S", "position": 452, "mutations": "S:L452Q", "comment": "L452Q is present in the Lambda and Omicron BA.12.1 variants. By itself, it is associated with ~20-fold reduced susceptibility to romlusevimab and 2-4 fold reduced susceptibility to casirivimab and imdevimab[^Tada21d][^Wang22d]. ", "date_added": "2021-07-15", "date_updated": "2022-06-04", "": ""}, {"gene": "S", "position": 453, "mutations": "S:Y453F", "comment": "Y453F is an ACE2-binding site RBD mutation that emerged several times in mink lineages, including one that subsequently spread among humans (B.1.1.298; cluster 5), which is no longer active[^Garcia-Beltran21]. Y453F increases ACE2 binding but remains rare[^Bayarri-Olmos21][^Gobeil21b][^Starr20]. Y453F is associated with high-level resistance to casirivimab[^Baum20][^Wang21f]. It retains susceptibility to plasma from convalescent and vaccinated persons[^Hoffmann21][^Wang21].", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 455, "mutations": "S:L455F", "comment": "L455F is a rare mutation that reduces susceptibility to casirivimab, C144, and several mAbs that are not in clinical trials[^Baum20][^Copin21][^Weisblum20][^Muecksch21].", "date_added": "2021-08-06", "date_updated": "", "": ""}, {"gene": "S", "position": 460, "mutations": "S:N460KST", "comment": "N460T is an essentially unreported mutation that has been selected in vitro by etesivimab and been found to reduce etesevimab susceptibility by >100-fold.", "date_added": "2021-08-07", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 477, "mutations": "S:S477N", "comment": "S477N is a common RBD mutation that has gradually increased in prevalence since the start of the pandemic and is present in the each of the Omicron variants. It increases the strength of ACE2 binding[^Starr20][^Zahradnik21]. It has not been shown to reduce susceptibility to any of the FDA EUA-approved mAbs[^Copin21][^Wang21f].", "date_added": "2021-04-05", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 478, "mutations": "S:T478IK", "comment": "T478K is an RBD mutation present in the Delta variant and in each of the Omicron variants. It does not appear to reduce to any of the clinical stage mAbs or to convalescent of vaccinee plasma. ", "date_added": "2021-04-08", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 484, "mutations": "S:E484K", "comment": "E484 is recognized by a high proportion of the polyclonal Abs developing in SARS-CoV-2 infected persons[^Greaney21]. E484K was present in the Beta, Gamma, Iota, Theta, and Zeta variants and in several Alpha variant sublineages. E484K has been selected in vitro by bamlanivimab, casirivimab, and several other RBM class I and II mAbs[^Baum20][^Greaney20][^Liu21][^FDA21][^Weisblum20] and it reduces susceptibility to these mAbs[^Baum20][^Chen21][^Copin21][^Gottlieb21][^Wang21b]. It has also been associated with 2.4- to 5.4-fold reduced susceptibility to the combination of cilgavimab plus tixagevimab[^FDA21c]. E484K has resulted in 3 to 10-fold reduced susceptibility to about 30% and >10-fold reduced susceptibility to about 10% of convalescent plasma samples[^Greaney20][^Jangra21][^Liu21][^Tada21][^Wang21b]. It has also resulted in 3 to 10-fold reduced susceptibility to about 30% of plasma samples from persons immunized with one of the authorized mRNA vaccines[^Jangra21][^Liu21][^Tada21][^Wang21b].", "date_added": "2021-04-05", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 484, "mutations": "S:E484Q", "comment": "E484 is recognized by a high proportion of the polyclonal Abs developing in SARS-CoV-2 infected persons[^Greaney21]. E484A is associated with >100-fold reduced susceptibility to bamlanivimab and about 10-fold reduced susceptibility to casirivimab but it retains susceptibility to the remaining FDA-authorized mAbs[^Gottlieb21][Tada21c]. Pseudoviruses containing E484Q have been associated with >10-fold reduced susceptibility to about 30% of convalescent plasma samples and persons receiving BNT162b[^Greaney21][^Ferreira21].", "date_added": "2021-04-07", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 484, "mutations": "S:E484A", "comment": "E484 is recognized by a high proportion of the polyclonal Abs developing in SARS-CoV-2 infected persons[^Greaney21]. E484A is present in each of the Omicron variants. It has been selected in vitro by several mAbs and in vivo by bamlanivimab[^Peiffer-Smadja21] and casirivimab/imdevimab[^Choi20]. It causes high-level resistance to bamlanivimab/etesivimab and low-level resistance to casirivimab/imdevimab, and tixagevimab. ", "date_added": "2021-08-07", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 486, "mutations": "S:F486VS", "comment": "F486V is present in the Omicron BA.4 and BA.5 variants. It has also been selected in vitro by casirivimab and been shown to reduce bamlanivimab/etesevimab and casirivimab activity by >100-fold and cilgavimab/tixagevimab activity by about 10-fold. F486S is associated with high-level resistance to cilgavimab and tixagevimab.", "date_added": "2021-08-07", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 490, "mutations": "S:F490S", "comment": "F490S has been reported in several Alpha variant sublineages[^Grabowski21] and in the Lambda variant. It is associated with high-level resistance to bamlanivimab but retains susceptibility to the other FDA EUA-approved mAbs[^Gottlieb21][^FDA21].", "date_added": "2021-04-05", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 493, "mutations": "S:Q493KR", "comment": "Q493R/K have been selected in vitro by casirivimab, bamlanivimab and have been reported in patients with prolonged SARS-CoV-2 infections. Both are associated with high-level resistance to bamlanivimab/etesevimab and casirivimab. Q493R is present in each of the Omicron variants.", "date_added": "2021-04-08", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 494, "mutations": "S:S494P", "comment": "S494P has been reported to arise independently in multiple lineages.", "date_added": "2021-04-05", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 498, "mutations": "S:Q498HR", "comment": "Q498H is a rare RBD mutation which appears to increase binding to both the human[^Starr20] and mouse[^Huang21] ACE2 receptor. Q498R is present in each of the Omicron variants. It has been selected in vitro for higher ACE2 binding affinity particularly in combination with N501Y[^Zahradnik21]. Their effect on mAb susceptibility has not been fully studied.", "date_added": "2021-07-15", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 501, "mutations": "S:N501Y", "comment": "N501Y is an ACE2-binding site RBM mutation present in the Alpha, Beta, Gamma, and each of the Omicron variants. N501Y increases ACE2-binding[^Cheng21][^Liu21c][^Starr20][^Supasa21][^Zhu21] and increases virus replication in human upper airway cells[^Liu21c]. N501Y does not influence the binding and neutralization of most mAbs[^Chen21][^Copin21][^Rees-Spear21][^Shen21][^Wang21b][^Weisblum20]. N501Y alone is rarely associated with reduced susceptibility to convalescent plasma[^Edara21][^Rees-Spear21][^Shen21][^Wang21b] or plasma from persons receiving the BNT162b2, mRNA-1273, or NVX-CoV2373 vaccines[^Edara21][^Muik21][^Shen21][^Wang21b][^Wang21][^Xie21].", "date_added": "2021-04-05", "date_updated": "2022-06-06", "": ""}, {"gene": "S", "position": 570, "mutations": "S:A570D", "comment": "A570D is in S1 C-terminal domain mutation present in the Alpha variant. It does not reduce susceptibility to any of the mAbs in advanced clinical development or to plasma from convalescent or vaccinated persons[^Wang21b].", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 614, "mutations": "S:Q613H", "comment": "Q613H occurred in the A.23.1 variant. It was hypothesized to have an effect similar to D614G.", "date_added": "2021-07-15", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 614, "mutations": "S:D614G", "comment": "D614G began increasing in prevalence in late February 2020 and within several months rose to a global prevalence approximating 100%[^Korber20]. Virus clones containing D614G produce higher levels of replication in primary human airway cells and in the upper respiratory tracts of hamsters[^Hou20][^Plante20][^Zhou21d]. D614G disrupts one or more interprotomer contacts resulting in a greater likelihood that one or more of the three RBDs are in an open versus closed position[^Benton20][^Yurkovetskiy20]. D614G may also be responsible for increasing the number of spike proteins per virion[^Jackson20][^Zhang20h] and increasing the rate of S1/S2 cleavage[^Gobeil21]. In some studies, viruses with D614G have been slightly more susceptible to neutralization by mAbs, convalescent plasma, and plasma from vaccinated persons[^Weissman21][^Yurkovetskiy20] while in other studies they were slightly more resistant to neutralization[^Hou20][^Zou21].", "date_added": "2021-04-05", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 655, "mutations": "S:H655Y", "comment": "H655Y occurs in the Gamma and Omicron variants and many other SARS-CoV-2 lineages. It increases spike protein cleavage and replication in vitro[^Escalera21].", "date_added": "2021-09-09", "date_updated": "2022-06-04", "": ""}, {"gene": "S", "position": 675, "mutations": "S:Q675HR, S:Q677HP, S:N679K", "comment": "Mutations just upstream of the S1/S2 furin cleavage including Q675H/R, Q677H/P, and N679K have occurred independently in many SARS-CoV-2 global lineages[^Hodcroft21]. Q677H has been shown to increase viral infectivity and syncytia formation and to enhance resistance to neutralization by variants with RBD mutations[^Zeng21].", "date_added": "2021-04-05", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 681, "mutations": "S:P681HR", "comment": "P681H is proximal to the S1/S2 furin cleavage site. It is present in in the Alpha, Theta, and each of the Omicron variants. P681R is present in the Delta and Kappa variants. The increased positive charge associated with both mutations appears to influence virus tropism by increasing S1/S2 cleavage in human airway epithelial cells[^Brown21][^Johnson21][^Lubinsky21][^Frazier21].", "date_added": "2021-04-07", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 701, "mutations": "S:A701V", "comment": "A701V has been reported in several previous circulating variants. It does not appear to reduce susceptibility to any mAb or to plasma from convalescent or vaccinated persons[^Wang21b].", "date_added": "2021-04-08", "date_updated": "2022-06-05", "": ""}, {"gene": "S", "position": 716, "mutations": "S:T716I", "comment": "T716I is an S2 mutation present in the Alpha variant. It does not reduce susceptibility to any of the mAbs in advanced clinical development or to plasma from convalescent or vaccinated persons[^Wang21b].", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 982, "mutations": "S:S982A", "comment": "S982A is in the heptad repeat 1 part of S2. It is present in the Alpha variant. It does not reduce susceptibility to any of the mAbs in advanced clinical development[^Wang21b]. It minimally reduced susceptibility to a small proportion of convalescent plasma samples[^Wang21b].", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "S", "position": 1118, "mutations": "S:D1118H", "comment": "D1118H is an S2 mutation present in the Alpha variant. It does not reduce susceptibility to any of the mAbs in advanced clinical development or to plasma from convalescent or vaccinated persons[^Wang21b].", "date_added": "2021-04-07", "date_updated": "2021-07-15", "": ""}, {"gene": "N", "position": 3, "mutations": "N:D3L", "comment": "N:D3L is a mutation in the Alpha variant that has been shown to introduce an enhanced transcription regulator sequence upstream of Orf9b, an IFN antagonist expressed as an alternative reading frame within the nucleocapsid coding region[^Thorne21].", "date_added": "2021-07-15", "date_updated": "2021-11-27", "": ""}, {"gene": "N", "position": 203, "mutations": "N:R203K, N:G204R", "comment": "N:R203K/G204R is a recurrent double amino acid mutation resulting from an adjacent 3-nucleotide change in the nucleocapsid gene. It likely arose by homologous recombination of the core sequence of the leader transcription regulatory sequence and it least to novel sub-genomic transcripts that have been hypothesized to antagonize host innate immunity[^Leary21].", "date_added": "2021-07-15", "date_updated": "", "": ""}]}